Sanofi India Limited
Sanofi India is engaged in Business of Manufacture and sale of pharmaceutical products.
What Sanofi files
- Others83
- Updates25
- Important18
- Board Meeting11
- Investor Meet9
- Dividend/Bonus6
Sanofi India secured a GST refund of ₹1.33 Cr, with the tax authority accepting its request to not adjust it against a ₹0.76 Cr outstanding demand. The company expects no material financial impact.
Sanofi India received a favorable tax order, vacating a demand of ₹0.73 Cr related to TDS on year-end provisions. The company reports no material financial or operational impact from this development.
Sanofi India posted strong Q2 results: domestic sales rose 8%, with Profit Before Tax up 19% to ₹112.3 Cr. Growth was led by a 14% increase in the insulin portfolio and 70% acceleration in the public sector business. The CFO is stepping down.
Sanofi India reported strong Q2 results: Net sales rose 6% and PBT before exceptional items increased 19% to ₹112.3 Cr, driven by 14% diabetes portfolio growth. The Board reconstituted committees, and the CFO will step down effective Sept 30.
Sanofi India reported strong Q2 results: net sales rose 6%, PBT jumped 19% to ₹112.3 Cr. The diabetes portfolio fueled 14% growth and market share gains. Additionally, the Whole Time Director and CFO is stepping down by September end.